- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| Mo | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| So | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 18.06. | VITA LIFE SCIENCES LIMITED: Cleasing Statement | - | ASX | ||
| 18.06. | VITA LIFE SCIENCES LIMITED: Application for quotation of securities - VLS | - | ASX | ||
| 12.06. | VITA LIFE SCIENCES LIMITED: Guidance | - | ASX | ||
| 11.06. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 09.06. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 09.06. | VITA LIFE SCIENCES LIMITED: Notification regarding unquoted securities - VLS | - | ASX | ||
| 09.06. | VITA LIFE SCIENCES LIMITED: Notification regarding unquoted securities - VLS | - | ASX | ||
| 05.06. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 01.06. | VITA LIFE SCIENCES LIMITED: On Market Share Buy Back | - | ASX | ||
| 01.06. | VITA LIFE SCIENCES LIMITED: Notification of buy-back - VLS | - | ASX | ||
| 29.05. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 28.05. | VITA LIFE SCIENCES LIMITED: Results of Meeting | - | ASX | ||
| 28.05. | VITA LIFE SCIENCES LIMITED: AGM Address and Presentation | - | ASX | ||
| 21.05. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 21.05. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 19.05. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 18.05. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 6,750 | +0,75 % | Green Thumb Industries Inc: Green Thumb Industries to release Q2 results Aug. 4 | ||
| ALNYLAM PHARMACEUTICALS | 278,00 | +0,72 % | Canaccord reiterates Alnylam stock Buy rating after RNAi event | ||
| NEKTAR THERAPEUTICS | 61,42 | -1,88 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,080 | -0,74 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| ADASTRA | 0,115 | 0,00 % | CSE Bulletin: Suspensions - Adastra Holdings Ltd., CAT Strategic Metals Corporation, Greenrise Global Brands Inc., StickIt Technologies Inc. | Le 12 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 12,850 | -0,77 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 22,480 | -0,97 % | H.C. Wainwright bestätigt Kaufempfehlung für Acadia Pharmaceuticals nach EU-Fortschritt | ||
| CATALYST PHARMACEUTICALS | 27,100 | -0,73 % | Santhera Pharmaceuticals Holding AG: Santhera gibt Topline-Ergebnisse der klinischen Phase-1-Studie von Catalyst Pharmaceuticals zu AGAMREE bekannt | Die Daten untermauern das Potenzial von AGAMREE als Therapie für ein breites Spektrum chronisch-entzündlicher seltener Erkrankungen
Pratteln, Schweiz, 1. Juli 2026 - Santhera Pharmaceuticals (SIX:... ► Artikel lesen | |
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2026ISIN NameAU000000BMG3 BMG... ► Artikel lesen | |
| OPUS GENETICS | 3,640 | +1,68 % | Opus Genetics, Inc.: Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases | Rapidly Advancing Five IRD Programs? with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months Cash Runway into... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 73,00 | -3,31 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance | Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin- Gel net revenues of $75.1 million, an increase of 42.1% year-over-yearQuarterly GAAP net income available... ► Artikel lesen | |
| SOLIGENIX | 0,389 | +0,44 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results | PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| ZELIRA THERAPEUTICS | 0,300 | 0,00 % | ZELIRA THERAPEUTICS LIMITED: Change of Director's Interest Notice | ||
| SAVARA | 5,284 | -2,80 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 2,890 | -1,70 % | Biodexa Pharmaceuticals PLC: Result of Annual General Meeting | June 30, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Result of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical... ► Artikel lesen |
Das Unternehmen VITA LIFE SCIENCES LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.